(Q38217060)

31 August 2017

title

Targeting the androgen receptor in prostate cancer (English)

1 reference

31 August 2017

1 reference

Zoran Culig

1

1 reference

31 August 2017

language of work or name

English

0 references

publication date

2 June 2014

1 reference

Expert Opinion on Pharmacotherapy

31 August 2017

published in

1 reference

31 August 2017

volume

15

1 reference

31 August 2017

issue

10

1 reference

31 August 2017

page(s)

1427-1437

1 reference

Differential androgen receptor signals in different cells explain why androgen-deprivation therapy of prostate cancer fails

31 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.915313

Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.915313

Anti-androgens and the mutated androgen receptor of LNCaP cells: differential effects on binding affinity, heat-shock protein interaction, and transcription activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.915313

The transcriptional co-activator cAMP response element-binding protein-binding protein is expressed in prostate cancer and enhances androgen- and anti-androgen-induced androgen receptor function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.915313

Promotion of agonist activity of antiandrogens by the androgen receptor coactivator, ARA70, in human prostate cancer DU145 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.915313

Mechanisms of action of novel agents for prostate cancer chemoprevention.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.915313

A nonsteroidal anti-inflammatory drug, flufenamic acid, inhibits the expression of the androgen receptor in LNCaP cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.915313

Combined inhibitory effects of green tea polyphenols and selective cyclooxygenase-2 inhibitors on the growth of human prostate cancer cells both in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.915313

Silymarin inhibits function of the androgen receptor by reducing nuclear localization of the receptor in the human prostate cancer cell line LNCaP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.915313

Herbal extract of Wedelia chinensis attenuates androgen receptor activity and orthotopic growth of prostate cancer in nude mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.915313

Gene expression changes following androgen receptor elimination in LNCaP prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.915313

Reduced expression of the androgen receptor by third generation of antisense shows antitumor activity in models of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.915313

Androgen deprivation increases p300 expression in prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.915313

Selective roles for cAMP response element-binding protein binding protein and p300 protein as coregulators for androgen-regulated gene expression in advanced prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.915313

Small molecule inhibition of the steroid receptor coactivators, SRC-3 and SRC-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.915313

Dynamic regulation of estrogen receptor-beta expression by DNA methylation during prostate cancer development and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.915313

Estrogen receptor (ER)-beta isoforms: a key to understanding ER-beta signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.915313

The anti-oestrogen fulvestrant (ICI 182,780) reduces the androgen receptor expression, ERK1/2 phosphorylation and cell proliferation in the rat ventral prostate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.915313

Androgen receptor regulation by physiological concentrations of the isoflavonoid genistein in androgen-dependent LNCaP cells is mediated by estrogen receptor beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.915313

Bisphenol A facilitates bypass of androgen ablation therapy in prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.915313

Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.915313

Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.915313

TMPRSS2-ERG status in circulating tumor cells as a predictive biomarker of sensitivity in castration-resistant prostate cancer patients treated with abiraterone acetate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.915313

Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.915313

Effects of sorafenib on C-terminally truncated androgen receptor variants in human prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.915313

Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.915313

Abiraterone in metastatic prostate cancer without previous chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.915313

Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.915313

The Hsp90 inhibitor, 17-AAG, prevents the ligand-independent nuclear localization of androgen receptor in refractory prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.915313

Hsp90 inhibitor 17-AAG inhibits progression of LuCaP35 xenograft prostate tumors to castration resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.915313

A novel HSP90 inhibitor delays castrate-resistant prostate cancer without altering serum PSA levels and inhibits osteoclastogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.915313

Clusterin inhibition using OGX-011 synergistically enhances Hsp90 inhibitor activity by suppressing the heat shock response in castrate-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.915313

Chemical ablation of androgen receptor in prostate cancer cells by the histone deacetylase inhibitor LAQ824.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.915313

Beta2-microglobulin signaling blockade inhibited androgen receptor axis and caused apoptosis in human prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.915313

Androgen receptor survival signaling is blocked by anti-beta2-microglobulin monoclonal antibody via a MAPK/lipogenic pathway in human prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.915313

STAT5A/B gene locus undergoes amplification during human prostate cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.915313

Transcription factor Stat5 knockdown enhances androgen receptor degradation and delays castration-resistant prostate cancer progression in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.915313

MicroRNA let-7c suppresses androgen receptor expression and activity via regulation of Myc expression in prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.915313

ASC-J9 suppresses castration-resistant prostate cancer growth through degradation of full-length and splice variant androgen receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.915313

New therapeutic approach to suppress castration-resistant prostate cancer using ASC-J9 via targeting androgen receptor in selective prostate cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.915313

Inhibition of the androgen receptor as a novel mechanism of taxol chemotherapy in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.915313

Tubulin-Targeting Chemotherapy Impairs Androgen Receptor Activity in Prostate Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.915313

Androgen receptor splice variants determine taxane sensitivity in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.915313

Development of a second-generation antiandrogen for treatment of advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.915313

Opposing effects of androgen deprivation and targeted therapy on prostate cancer prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.915313

Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.915313

Increased survival with enzalutamide in prostate cancer after chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.915313

Enzalutamide in castration-resistant prostate cancer patients progressing after docetaxel and abiraterone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.915313

FoxA1 corrupts the antiandrogenic effect of bicalutamide but only weakly attenuates the effect of MDV3100 (Enzalutamide™).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.915313

Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.915313

A novel antiandrogen, Compound 30, suppresses castration-resistant and MDV3100-resistant prostate cancer growth in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.915313

Differential androgen deprivation therapies with anti-androgens casodex/bicalutamide or MDV3100/Enzalutamide versus anti-androgen receptor ASC-J9(R) Lead to promotion versus suppression of prostate cancer metastasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.915313

NF-κB2/p52 induces resistance to enzalutamide in prostate cancer: role of androgen receptor and its variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.915313

Anti-androgen receptor ASC-J9 versus anti-androgens MDV3100 (Enzalutamide) or Casodex (Bicalutamide) leads to opposite effects on prostate cancer metastasis via differential modulation of macrophage infiltration and STAT3-CCL2 signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.915313

Inhibition of constitutively active Stat3 reverses enzalutamide resistance in LNCaP derivative prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.915313

A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.915313

An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.915313

Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.915313

Effect of a novel 17,20-lyase inhibitor, orteronel (TAK-700), on androgen synthesis in male rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.915313

Phase I/II trial of orteronel (TAK-700)--an investigational 17,20-lyase inhibitor--in patients with metastatic castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.915313

ARN-509: a novel antiandrogen for prostate cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.915313

Direct regulation of androgen receptor activity by potent CYP17 inhibitors in prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.915313

Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.915313

Cross-talk between the androgen receptor and the phosphatidylinositol 3-kinase/Akt pathway in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.915313

Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.915313

Synergistic targeting of PI3K/AKT pathway and androgen receptor axis significantly delays castration-resistant prostate cancer progression in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.915313

The activity of the androgen receptor variant AR-V7 is regulated by FOXO1 in a PTEN-PI3K-AKT-dependent way.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.915313

Inhibition of the acetyltransferases p300 and CBP reveals a targetable function for p300 in the survival and invasion pathways of prostate cancer cell lines

21 January 2018

1 reference

27 May 2022

https://opencitations.net/index/coci/api/v1/citations/10.1158/1535-7163.MCT-11-0182

Identifiers

DOI

10.1517/14656566.2014.915313

1 reference

31 August 2017

1 reference